Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
This study aimed to assess whether dienogest (DNG) is also effective in patients with recurrent endometriosis based on multicenter data of 121 women who were clinically diagnosed as having recurrent endometriosis and treated for more than 24 weeks with DNG (2 mg daily). We evaluated the changes in endometriosis-associated pain scores (visual analog scale [VAS]), serum cancer antigen 125 (CA-125) levels, and endometrioma sizes following DNG medication in these women along with adverse events associated with DNG medication. The mean duration of DNG treatment was 57.80 (24.08) weeks, and during continuation of DNG, the mean VAS score was 5.03 (1.73) at baseline and significantly decreased to 2.46 (1.32) at 24 weeks after taking DNG. In subgroup analysis, the trend of pain-related symptoms was compared between the symptom-only recurrence group and the recurrent endometrioma group. In both groups, the pain scores decreased significantly during the first 24 weeks but remained relatively unchanged thereafter. Moreover, the size of recurrent endometriomas and CA-125 levels also decreased significantly compared to baseline. The mean size of recurrent endometriomas was 3.77 (1.59) cm in diameter and decreased to 2.74 (1.53) cm after 24 weeks of DNG treatment ( P for trend < .001). The mean CA-125 level was 80.04 U/mL at baseline and significantly decreased to 33.11 U/mL after taking DNG for 24 weeks and lasted until 72 weeks ( P for trend = .0288). Overall, 51 (42.15%) patients reporte…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DNG, a 19-nortestosterone derivative, is the most recent progestin available and labelled for endometriosis and according to a number of evidences it substantially improves endometriosis-related pain symptoms in long term treatment [186].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [186]
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
DeLoach, L. J., Higgins, M. S., Caplan, A. B., & Stiff, J. L. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199801000-00020 · Cited by 722
Increasing the reliability and validity of pain intensity measurement in chronic pain patients
Jensen, M. P., & McFarland, C. A. (1993) · Pain · doi:10.1016/0304-3959(93)90148-i · Cited by 720
A Unified Approach to Mixed Linear Models
McLean, R. A., Sanders, W. L., & Stroup, W. W. (1991) · The American Statistician · doi:10.1080/00031305.1991.10475767 · Cited by 601 · cited 1×
“To overcome the shortcoming that resulted from a lot of missing values, linear mixed-effects models were chosen for analyses, which is powerful in handling missing values, especially in the context of longitudinal designs.(44) In conclusion, the present retrospective study has shown that DNG is effective in reducing t…”
MethodStrowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381 · cited 4×
“42 for the primary outcome.(13) A total of 6 evaluable patients were required to yield a power (1 b) of 90% to demonstrate the efficacy of DNG treatment.”
BackgroundResultInfluentialThe performance of CA-125 measurement in the detection of endometriosis: a meta-analysis
Mol, B. W. J., Bayram, N., Lijmer, J. G., Wiegerinck, M. A. H. M., Bongers, M. Y., van der Veen, F., & Bossuyt, P. M. M. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00355-0 · Cited by 355
Surgical Treatment of Endometriosis: A 7-Year Follow-up on the Requirement for Further Surgery
Shakiba, K., Bena, J. F., McGill, K. M., Minger, J., & Falcone, T. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181758ec6 · Cited by 339 · cited 1×
“Without postoperative medication, 45% to 55% of patients who had been treated surgically require further surgery by 5 to 7 years because of recurrent endometriosis.(4) Recent reports suggest that second surgery for recurrent endometrioma is associated with a higher loss of ovarian tissue and ovarian reserve evaluated…”
BackgroundGuo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
Elevated serum concentrations of CA-125 in patients with advanced endometriosis
Barbieri, R. L., Niloff, J. M., Bast, R. C., Schaetzl, E., Kistner, R. W., & Knapp, R. C. (1986) · Fertility and Sterility · doi:10.1016/s0015-0282(16)49333-7 · Cited by 320
Endometriomas: their ultrasound characteristics
Van Holsbeke, C., Van Calster, B., Guerriero, S., Savelli, L., Paladini, D., Lissoni, A. A., Czekierdowski, A., Fischerova, D., Zhang, J., Mestdagh, G., et al. (2010) · Ultrasound in Obstetrics & Gynecology · doi:10.1002/uog.7668 · Cited by 299 · cited 1×
“The diagnosis of an ovarian endometrioma was based on transvaginal or transrectal ultrasonography, fulfilling the following ultrasonographic criteria a round mass with a thick wall, a minimum diameter of 2 cm, regular margins, and homogenous low echogenic fluid content with scattered internal echoes, without papillary…”
MethodSutton, C. J. G., Pooley, A. S., Ewen, S. P., & Haines, P. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00403-2 · Cited by 250 · cited 1×
“However, even after excising all visible disease and restoring normal anatomic relationships of pelvic organs, symptoms recur in at least 10% to 20% of treated women per year.(2,3) Without postoperative medication, 45% to 55% of patients who had been treated surgically require further surgery by 5 to 7 years because o…”
BackgroundSeracchioli, R., Mabrouk, M., Frascà, C., Manuzzi, L., Montanari, G., Keramyda, A., & Venturoli, S. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.052 · Cited by 228
Strowitzki, T., Faustmann, T., Gerlinger, C., & Seitz, C. (2010) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2010.04.002 · Cited by 227 · cited 1×
“3%) case lacking efficacy of DNG was reported in pooled analysis including 4 phase II and phase III trials performed in Europe that investigated 514 women with confirmed endometriosis.(10,13,16,30,31) Direct comparison with previous studies is difficult because participants of previous studies are composed of patients…”
ResultThe efficiency of transvaginal ultrasonography in the diagnosis of endometrioma
Mais, V., Guerriero, S., Ajossa, S., Angiolucci, M., Paoletti, A. M., & Melis, G. B. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56275-x · Cited by 220 · cited 1×
“Previous studies of transvaginal ultrasonography findings reported a sensitivity of 77% to 89% and a specificity of 89% to 98% in diagnosing endometriomas using these criteria.(24,25) The size of an endometrioma was defined as its maximum diameter in any 1516 Reproductive Sciences 25(10)”
MethodCasper, R. F. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.01.003 · Cited by 205 · cited 1×
“Although OCs are the most commonly prescribed medication for endometriosis for decades, OCs have been criticized for lack of evidence for therapeutic efficacy and for increasing the risk of thromboembolism,(7,8) and progestinonly pill is suggested as a better first-line treatment option for endometriosis by some inves…”
BackgroundReduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment
Petraglia, F., Hornung, D., Seitz, C., Faustmann, T., Gerlinger, C., Luisi, S., Lazzeri, L., & Strowitzki, T. (2012) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-011-1941-7 · Cited by 200 · cited 1×
“3%) case lacking efficacy of DNG was reported in pooled analysis including 4 phase II and phase III trials performed in Europe that investigated 514 women with confirmed endometriosis.(10,13,16,30,31) Direct comparison with previous studies is difficult because participants of previous studies are composed of patients…”
ResultProgesterone Receptor Isoform A But Not B Is Expressed in Endometriosis1
Attia, G. R., Zeitoun, K., Edwards, D., Johns, A., Carr, B. R., & Bulun, S. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6739 · Cited by 193
Sasagawa, S., Shimizu, Y., Kami, H., Takeuchi, T., Mita, S., Imada, K., Kato, S., & Mizuguchi, K. (2008) · Steroids · doi:10.1016/j.steroids.2007.10.003 · Cited by 177 · cited 2×
“However, DNG has been reported to directly reduce endometriotic lesion through inducing hypoestrogenic, hypergestagenic local endocrine environment.(15,34) Nevertheless, considering DNG is also a kind of progestin, there may be participants who do not exhibit tissue-direct effects by DNG, and the prevalence of DNG res…”
BackgroundOral contraceptives and risk of endometriosis: a systematic review and meta-analysis
Vercellini, P., Eskenazi, B., Consonni, D., Somigliana, E., Parazzini, F., Abbiati, A., & Fedele, L. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq042 · Cited by 176
Köhler, G., Faustmann, T. A., Gerlinger, C., Seitz, C., & Mueck, A. O. (2010) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2009.08.020 · Cited by 159 · cited 1×
“3%) case lacking efficacy of DNG was reported in pooled analysis including 4 phase II and phase III trials performed in Europe that investigated 514 women with confirmed endometriosis.(10,13,16,30,31) Direct comparison with previous studies is difficult because participants of previous studies are composed of patients…”
ResultMuzii, L., Achilli, C., Lecce, F., Bianchi, A., Franceschetti, S., Marchetti, C., Perniola, G., & Panici, P. B. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2014.12.101 · Cited by 141 · cited 1×
“Recent reports suggest that second surgery for recurrent endometrioma is associated with a higher loss of ovarian tissue and ovarian reserve evaluated by antimüllerian hormone, antral follicle count, and ovarian volume compared to first surgery.(5,6) Therefore, preventing recurrence after surgical treatment is becomin…”
BackgroundPanel of markers can accurately predict endometriosis in a subset of patients
Seeber, B., Sammel, M. D., Fan, X., Gerton, G. L., Shaunik, A., Chittams, J. L., & Barnhart, K. T. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.05.014 · Cited by 129
Strowitzki, T., Faustmann, T., Gerlinger, C., Schumacher, U., Ahlers, C., & Seitz, C. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s77202 · Cited by 120 · cited 2×
“4%).(10) In contrast, in the present study, only 2 (1.”
ResultHayashi, A., Tanabe, A., Kawabe, S., Hayashi, M., Yuguchi, H., Yamashita, Y., Okuda, K., & Ohmichi, M. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-31 · Cited by 109 · cited 1×
“Another study has also shown that DNG could improve the responsiveness to progestin treatment in endometriotic tissue by increasing the progesterone receptor isoform B/A ratio.(29) However, for 16 (13.”
BackgroundChoi, J., Jo, M., Lee, E., Lee, D., & Choi, D. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.05.020 · Cited by 93
Self-citationDienogest: A New Therapeutic Agent for the Treatment of Endometriosis
Harada, T., & Taniguchi, F. (2010) · Women's Health · doi:10.2217/whe.09.72 · Cited by 92 · cited 1×
“It exerts minimal androgenic, mineralocorticoid, and glucocorticoid activitieswith onlymoderate suppression of estrogen levels.(11,14,15) In a randomized, multicenter trial of 252 participants, DNG showed equivalent efficacy to depot leuprolide in relieving the pain associated with endometriosis.”
BackgroundFerrero, S., Scala, C., Racca, A., Calanni, L., Remorgida, V., Venturini, P. L., & Maggiore, U. L. R. (2015) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.01.032 · Cited by 83 · cited 1×
“Recent reports suggest that second surgery for recurrent endometrioma is associated with a higher loss of ovarian tissue and ovarian reserve evaluated by antimüllerian hormone, antral follicle count, and ovarian volume compared to first surgery.(5,6) Therefore, preventing recurrence after surgical treatment is becomin…”
BackgroundKlipping, C., Duijkers, I., Remmers, A., Faustmann, T., Zurth, C., Klein, S., & Schuett, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011423664 · Cited by 83 · cited 1×
“However, DNG has been reported to directly reduce endometriotic lesion through inducing hypoestrogenic, hypergestagenic local endocrine environment.(15,34) Nevertheless, considering DNG is also a kind of progestin, there may be participants who do not exhibit tissue-direct effects by DNG, and the prevalence of DNG res…”
BackgroundSafety of medical treatments for endometriosis
Berlanda, N., Somigliana, E., Viganò, P., & Vercellini, P. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1121991 · Cited by 78 · cited 1×
“Although OCs are the most commonly prescribed medication for endometriosis for decades, OCs have been criticized for lack of evidence for therapeutic efficacy and for increasing the risk of thromboembolism,(7,8) and progestinonly pill is suggested as a better first-line treatment option for endometriosis by some inves…”
BackgroundRepetitive conservative surgery for recurrence of endometriosis.
Candiani, G. B., Fedele, L., Vercellini, P., Bianchi, S., & Nola, G. D. (1991) · PubMed · Cited by 77
Exacoustós, C., Zupi, E., Carusotti, C., Rinaldo, D., Marconi, D., Lanzi, G., & Arduini, D. (2003) · The Journal of the American Association of Gynecologic Laparoscopists · doi:10.1016/s1074-3804(05)60266-6 · Cited by 76
Kurjak, A., & Kupesic, S. P. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56820-4 · Cited by 68 · cited 1×
“Previous studies of transvaginal ultrasonography findings reported a sensitivity of 77% to 89% and a specificity of 89% to 98% in diagnosing endometriomas using these criteria.(24,25) The size of an endometrioma was defined as its maximum diameter in any 1516 Reproductive Sciences 25(10)”
MethodCheng, Y.-H., Imir, A. G., Fenkçi, V., Yılmaz, M. B., & Bulun, S. E. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.12.014 · Cited by 62 · cited 1×
“of progesterone receptor is known to be extremely low in endometriotic tissues, which results in progesterone resistance.(32,33) For this reason, progestins were thought to reduce pain by suppressing or attenuating ovulation in patients with endometriosis.”
BackgroundThe pharmacological profile of dienogest
Oettel, M., Breitbarth, H., Elger, W., Gräser, T., Hübler, D., Kaufmann, G., Moore, C., Patchev, V., Römer, W., Schröder, J., et al. (1999) · The European Journal of Contraception & Reproductive Health Care · doi:10.3109/13625189909085259 · Cited by 61 · cited 1×
“It exerts minimal androgenic, mineralocorticoid, and glucocorticoid activitieswith onlymoderate suppression of estrogen levels.(11,14,15) In a randomized, multicenter trial of 252 participants, DNG showed equivalent efficacy to depot leuprolide in relieving the pain associated with endometriosis.”
BackgroundUse of dienogest over 53 weeks for the treatment of endometriosis
Sugimoto, K., Nagata, C., Hayashi, H., Yanagida, S., & Okamoto, A. (2015) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.12811 · Cited by 60
Lee, D.-Y., Bae, D.-S., Yoon, B.-K., & Choi, D. (2010) · Human Reproduction · doi:10.1093/humrep/deq279 · Cited by 54 · cited 2×
“The diagnosis of an ovarian endometrioma was based on transvaginal or transrectal ultrasonography, fulfilling the following ultrasonographic criteria a round mass with a thick wall, a minimum diameter of 2 cm, regular margins, and homogenous low echogenic fluid content with scattered internal echoes, without papillary…”
BackgroundMethodSelf-citationDiagnostic value of serum CA125, CA19-9 and CA15-3 in endometriosis: A meta-analysis
Shen, A., Xu, S., Ma, Y., Guo, H., Li, C., Yang, C., & Zou, S. (2015) · Journal of International Medical Research · doi:10.1177/0300060515583076 · Cited by 44 · cited 1×
“Moreover, recent meta-analysis found that the serum CA-125 level was associated with endometriosis in Caucasian, Asian, and overall populations, and with both early and advanced stage disease.(36) Considering this study was aimed at Korean women with various stages of recurrent endometriosis, CA-125 has value as an in…”
ResultEfficacy and Safety of Long-Term Use of Dienogest in Women With Ovarian Endometrioma
Lee, S. R., Yi, K. W., Song, J. Y., Seo, S. K., Lee, D.-Y., Cho, S., & Kim, S. H. (2018) · Reproductive Sciences · doi:10.1177/1933719117725820 · Cited by 39 · cited 1×
“3%).(43) Despite no data, it might be also due to progesterone resistance in those with recurrent endometriosis, which might cause higher failure rate in treatment as well as higher rate of uterine bleeding.”
BackgroundSelf-citationLong-Term Administration of Dienogest Reduces Recurrence after Excision of Endometrioma
Ota, Y., Andou, M., Yanai, S., Nakajima, S., Fukuda, M., Takano, M., Kurotsuchi, S., Ebisawa, K., Hada, T., & Ota, I. (2015) · Journal of Endometriosis and Pelvic Pain Disorders · doi:10.5301/je.5000219 · Cited by 38 · cited 1×
“In contrast to GnRH agonist that have risk of bone loss following longterm use, DNG also showed favorable safety profile in a study of 151 participants with a mean follow-up of 61 weeks.(12) Although DNG has improved endometriosis-related symptoms and reduced recurrence after surgical treatment of endometriosis in pre…”
BackgroundEndometrial antibodies versus CA-125 for the detection of endometriosis
Wild, R. A., Hirisave, V., Bianco, A., Podczaski, E. S., & Demers, L. M. (1991) · Fertility and Sterility · doi:10.1016/s0015-0282(16)54065-5 · Cited by 35 · cited 1×
“CA-125 has high specificity but low sensitivity which is the disadvantage as a biomarker for the diagnosis of endometriosis.(35) However, since all patients included in this study has a history of histologically diagnosed endometriosis, increase in serum CA-125 concentration is more likely to be the result of endometr…”
BackgroundCA 125 levels measured in different phases of the menstrual cycle in screening for endometriosis.
O'Shaughnessy, A., Check, J. H., Nowroozi, K., & Lurie, D. (1993) · PubMed · Cited by 35
Matalliotakis, I., Goumenou, A. G., Mülayim, N., Karkavitsas, N. S., & Koumantakis, E. E. (2004) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-004-0645-7 · Cited by 24
Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometriotic Cell Line EEC 145
Gaetje, R., Winnekendonk, D. W., Scharl, A., & Kaufmann, M. (1999) · Journal of the Society for Gynecologic Investigation · doi:10.1177/107155769900600510 · Cited by 14
Ovarian Cancer Antigen CA 125 Enhances the Invasiveness of the Endometriotic Cell Line EEC 145
Gaetje, R., Winnekendonk, D. W., Scharl, A., & Kaufmann, M. (1999) · Journal of the Society for Gynecologic Investigation · doi:10.1016/s1071-5576(99)00027-1 · Cited by 14
Research works printed but not linked: 1
- DeLoach L, Higgins M, Caplan A, Stiff J. The visual analog scale in the immediate postoperative period. Anesth Analg. 1998; 86(1):102–106.
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Use of dienogest in endometriosis: a narrative literature review and expert commentary
Murji, A., Biberoğlu, K., Leng, J., Mueller, M. D., Römer, T., Vignali, M., & Yarmolinskaya, M. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1744120 · Cited by 116
Barra, F., Scala, C., Maggiore, U. L. R., & Ferrero, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010154 · Cited by 61
“Moreover, in line with previous studies [32,33], the rate of patients experiencing amenorrhea was around 65%, and this status correlated to the almost complete disappearance of menstrual‐related symptoms, and, in particular, dysmenorrhea.”
ResultMuzii, L., Galati, G., Di Tucci, C., Di Feliciantonio, M., Perniola, G., Di Donato, V., Benedetti Panici, P., & Vignali, M. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1640199 · Cited by 55
“report a decrease in size of 27% after 6months, and of 52% after 14months of dienogest therapy, in a series of 88 patients with ovarian endometriomas [15].”
BackgroundChoi, S. H., Kim, S., Lee, S. W., Won, S., Shim, S. H., Lee, N., Kim, M. K., Jung, Y. W., Seong, S. J., & Kim, M. (2023) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0278 · Cited by 24
Self-citation
Metadata
- Authors
- Lee, J. H., Song, J. Y., Yi, K. W., Lee, S. R., Lee, D.-Y., Shin, J.-H., Cho, S., Seo, S. K., & Kim, S. H.
- Affiliations
- Yonsei University (KR)
- The Catholic University of Korea Uijeongbu St. Mary's Hospital (KR)
- Korea University (KR)
- Ewha Womans University (KR)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Corresponding author
- Seo, Seok Kyo
- Kim, Sung Hoon
- Venue
- Reproductive Sciences
- Published
- 2018-10
- Volume
- 25
- Issue
- 10
- Pages
- 1515-1522
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W2806443010
- Cited by
- 44
- References
- 44
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 4 · 2019: 4 · 2018: 2
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- dienogest, recurrent endometriosis, endometrioma size, CA125, endometriosis-associated pain, irregular bleeding, adverse events
- MeSH terms
- Adult, Amenorrhea, Endometriosis, Female, Hormone Antagonists, Humans, Nandrolone, Pain, Pain Measurement, Recurrence, Retrospective Studies, Multicenter Studies as Topic, Treatment Outcome, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.